Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ECO 2021 May 10 - 13

Treatment with Semaglutide 2.4 mg Leads to Improvements in Cardiometabolic Risk Factors in the STEP 1 Trial

W. Timothy Garvey1; Meena Bhatta2; Melanie Davies3; John E. Deanfield4; Usman Khalid2; Mikhail Kosiborod5; Robert Kushner6; Domenica M. Rubino7; Niels Zeuthen2; Subodh Verma8;
1Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA; 2Novo Nordisk A/S, Søborg, Denmark; 3Diabetes Research Centre, Department of Health Sciences, University of Leicester, Leicester, UK, and NIHR Leicester Biomedical Research Centre, Leicester, UK; 4Institute of Cardiovascular Science, University College London, London, UK; 5Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA; 6Division of Endocrinology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 7Washington Center for Weight Management and Research, Arlington, VA, USA; 8Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael’s Hospital, Unity Health Toronto, Toronto, ON, Canada.;